Intellia reports positive 3-year LONVO-Z data at HAE trials at EAACI Congress

Intellia Therapeutics, Inc. (NASDAQ:North) in 11 Best Genomics Stocks to Buy According to Hedge Funds. At EAACI Congress 2025, we encouraged 3 years of follow-up data from the Phase 1 trial of Lonvoguran Ziclumeran (Lonvo-Z) in patients with hereditary angioedema (HAE).

Lab scientists look through microscopes focusing on gene editing technology.

All 10 patients received a single dose of LONVO-Z followed by no median attack or treatment for 23 months, resulting in an average reduction of 98% in monthly HAE attacks. Positive safety results were maintained at all therapeutic doses. The current Phase 3 Haelo Trial has the majority of our registrations and has completed the screening earlier than expected. Intellia Therapeutics, Inc. (NASDAQ: NTLA) is scheduled to be released in 2027 after submitting the BLA in 2026.

LONVO-Z (NTLA-2002) is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA designated it as an orphan drug and RMAT, but the EMA, among other regulatory categories, is designating it as Prime.

This treatment, administered intravenously at doses ranging from 25 to 75 mg, demonstrated administration-dependent reduction in kallikrein protein and long-term efficacy, with no major treatment-related side effects documented.

Although we acknowledge the potential of NTLA investments, we believe certain AI stocks offer greater promotion opportunities and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: 10 High-Growth EV Stocks to Invest and 13 best car stocks to buy in 2025.

Disclosure. none.